Professor Charlie Craddock CBE is Director of the Blood and Marrow Transplant Unit at the Queen Elizabeth Hospital, Birmingham and Professor of Haemato-oncology at the University of Birmingham.
He studied medicine at Oxford University and underwent postgraduate training in haematology at the Hammersmith Hospital, London, the Institute of Molecular Medicine at the University of Oxford and the Fred Hutchinson Cancer Research Centre at the University of Washington, Seattle.
In 1999 he was appointed Director of the Blood and Marrow Transplant Unit at the Queen Elizabeth Hospital, Birmingham and in 2004 took up a newly created Chair of Haemato-oncology at the University of Birmingham. In the last decade the BMT unit at the Queen Elizabeth Hospital has grown rapidly to become the second largest adult transplant programme in the United Kingdom. Over the same period he has led the development of a translational haemato-oncology programme in Birmingham and is Director of the recently established Centre for Clinical Haematology which houses an integrated clinical leukaemia and transplant programme and an early phase trial unit serving one of the largest catchment areas in Europe.
Professor Craddock is Chair of UK Stem Cell Strategic Forum which was established in 2010 to advise the Department of Health on the strategic development of alternative donor stem cell transplantation in the UK. In 2011 he led a successful bid to establish a national haemato-oncology early phase trials programme- the Therapy Acceleration Programme.
He is a recent President of the British Society of Blood and Marrow Transplantation and is an active member of the NCRN Acute Myeloid Leukaemia Working Party. His main research interests include the development of novel drug and transplant therapies in myeloid leukaemias with particular reference to epigenetic and targeted therapies either prior to transplant or as adjunctive post-transplant therapy.
In December 2015, Professor Craddock was awarded a CBE in the New Year Honours list for 2016. The award is a recognition of his tremendous work in the field of medicine.
Cure Leukaemia's £1m Centre Appeal 2017